Non-nucleoside reverse transcriptase inhibitor failure impairs HIV-RNA responses to efavirenz-containing salvage antiretroviral therapy

AIDS. 2001 Aug 17;15(12):1581-4. doi: 10.1097/00002030-200108170-00019.

Abstract

In a retrospective cohort study of salvage antiretroviral combination therapy including efavirenz, 60% of 51 patients were able to suppress HIV RNA by at least 1 log10 or to less than 50 copies/ml. A lack of the previous use of non-nucleoside reverse transcriptase inhibitors was the only factor predictive of response on multivariate analysis. No patient with a viral isolate with an increased IC50 to efavirenz by virtual phenotype had a virological response

MeSH terms

  • Adult
  • Alkynes
  • Anti-HIV Agents / therapeutic use*
  • Benzoxazines
  • Cyclopropanes
  • Drug Therapy, Combination
  • HIV Infections / drug therapy
  • HIV Infections / virology*
  • HIV-1 / drug effects
  • HIV-1 / isolation & purification*
  • Humans
  • Male
  • Oxazines / therapeutic use*
  • RNA, Viral / blood*
  • Reverse Transcriptase Inhibitors / therapeutic use*
  • Salvage Therapy
  • Treatment Outcome

Substances

  • Alkynes
  • Anti-HIV Agents
  • Benzoxazines
  • Cyclopropanes
  • Oxazines
  • RNA, Viral
  • Reverse Transcriptase Inhibitors
  • efavirenz